Basal activity profiles of NPH and [Nε-palmitoyl Lys (B29)] human insulins in subjects with IDDM

被引:25
作者
Radziuk, J
Pye, S
Bradley, B
Braaten, J
Vignati, L
Roach, P
Bowsher, R
DiMarchi, R
Chance, R
机构
[1] Ottawa Civic Hosp, Diabet & Metab Res Unit, Ottawa, ON K1Y 4E9, Canada
[2] Lilly Res Labs, Indianapolis, IN USA
关键词
insulin; pharmacokinetics; acylated insulin; NPH; insulin therapy; glucose turnover;
D O I
10.1007/s001250050876
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[N-epsilon-palmitoyl Lys (B29)] human insulin is a fatty acid-acylated derivative of insulin with extended action compared to unmodified insulin when infused intravenously (i.v.) secondary to its binding to circulating albumin. The duration and activity profile of the activated (A) and NPH (B) insulins were assessed following subcutaneous (s.c.) doses of (A) 6 nmol/kg and (B) 1.2 nmol/kg (equivalent to 0.2 U/kg) in 3 subjects with IDDM. After overnight i.v. infusion of regular human insulin, morning glucose was (A) 6.9 +/- 0.1 and (B) 6.8 +/- 0.1 mmol/l. After the s.c. injection, i.v. human insulin or glucose was infused to maintain near-basal glycaemia and tracer glucose to assess hepatic glucose production (HGP). An activity profile was deduced for each study by expressing the glucose infusion rate at each time point, as a fraction (%) of the basal (measured) HGP, and the i.v. insulin infusion rate as a fraction (%) of the basal requirement, The two fractions are combined by adding the fractional glucose infusion rate and subtracting the fractional insulin infusion rate. Infusion rates of i.v. insulin in the morning were (A) 0.96 +/- 0.096 and (B) 1.22 +/- 0.09 pmol.kg(-1).min(-1). After insulin injection, i.v insulin requirements decreased and were below 10 % of basal between 100 and 150 min, A constant activity profile of 0 % represents a perfect substitution of the basal i.v. insulin infusion by the s.c. dose, The actual profile is defined by deviations from this (above) and was -17 +/- 11, 7 +/- 10, -9 +/- 6 and -18 +/- 18 % for [N-epsilon-palmitoyl Lys (B29)] human insulin and 17 +/- 12, 5 +/- 6, -9 +/- 15, 22 +/- 18 % for NPH insulin at 3, 6, 9 and 12 h after s.c. injection. HGP was similar for the two insulins, demonstrating similar metabolic actions and profiles both peripherally and al the liver.
引用
收藏
页码:116 / 120
页数:5
相关论文
共 10 条
[1]   MONOMERIC INSULINS AND THEIR EXPERIMENTAL AND CLINICAL IMPLICATIONS [J].
BRANGE, J ;
OWENS, DR ;
KANG, S ;
VOLUND, A .
DIABETES CARE, 1990, 13 (09) :923-954
[2]  
DiMarchi RD, 1992, PEPTIDES CHEM BIOL, P26
[3]   FACTORS INFLUENCING THE ABSORPTION, SERUM-INSULIN CONCENTRATION, AND BLOOD-GLUCOSE RESPONSES AFTER INJECTIONS OF REGULAR INSULIN AND VARIOUS INSULIN MIXTURES [J].
GALLOWAY, JA ;
SPRADLIN, CT ;
NELSON, RL ;
WENTWORTH, SM ;
DAVIDSON, JA ;
SWARNER, JL .
DIABETES CARE, 1981, 4 (03) :366-376
[4]  
LAURITZEN T, 1985, ACTA ENDOCRINOL-COP, V110, P45
[5]  
Markussen J, 1996, DIABETOLOGIA, V39, P281
[6]   A SIMPLE INSULIN INFUSION ALGORITHM FOR ESTABLISHING AND MAINTAINING OVERNIGHT NEAR-NORMOGLYCEMIA IN TYPE-I AND TYPE-II DIABETES [J].
MOKAN, M ;
GERICH, JE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (04) :943-945
[7]   Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs [J].
Myers, SR ;
YakubuMadus, FE ;
Johnson, WT ;
Baker, JE ;
Cusick, TS ;
Williams, VK ;
Tinsley, FC ;
Kriauciunas, A ;
Manetta, J ;
Chen, VJ .
DIABETES, 1997, 46 (04) :637-642
[8]   DIFFERENTIAL-EFFECTS OF A GRADED SELECTIVE SUPPRESSION OF INSULIN-SECRETION WITH GALANIN ON GLUCOSE-PRODUCTION AND REMOVAL IN DOGS [J].
RADZIUK, J ;
DAVIES, J ;
PYE, S ;
MCDONALD, TJ .
PANCREAS, 1994, 9 (04) :485-493
[9]   Bioavailability and bioeffectiveness of subcutaneous human insulin and two of its analogs - Lys(B28)Pro(B29)-human insulin and Asp(B10)Lys(B28)Pro(B29)-human insulin - Assessed in a conscious pig model [J].
Radziuk, JM ;
Davies, JC ;
Pye, WS ;
Shields, JE ;
DiMarchi, RD ;
Chance, RE .
DIABETES, 1997, 46 (04) :548-556
[10]   THE EFFECT OF INTENSIVE TREATMENT OF DIABETES ON THE DEVELOPMENT AND PROGRESSION OF LONG-TERM COMPLICATIONS IN INSULIN-DEPENDENT DIABETES-MELLITUS [J].
SHAMOON, H ;
DUFFY, H ;
FLEISCHER, N ;
ENGEL, S ;
SAENGER, P ;
STRELZYN, M ;
LITWAK, M ;
WYLIEROSETT, J ;
FARKASH, A ;
GEIGER, D ;
ENGEL, H ;
FLEISCHMAN, J ;
POMPI, D ;
GINSBERG, N ;
GLOVER, M ;
BRISMAN, M ;
WALKER, E ;
THOMASHUNIS, A ;
GONZALEZ, J ;
GENUTH, S ;
BROWN, E ;
DAHMS, W ;
PUGSLEY, P ;
MAYER, L ;
KERR, D ;
LANDAU, B ;
SINGERMAN, L ;
RICE, T ;
NOVAK, M ;
SMITHBREWER, S ;
MCCONNELL, J ;
DROTAR, D ;
WOODS, D ;
KATIRGI, B ;
LITVENE, M ;
BROWN, C ;
LUSK, M ;
CAMPBELL, R ;
LACKAYE, M ;
RICHARDSON, M ;
LEVY, B ;
CHANG, S ;
HEINHEINEMANN, M ;
BARRON, S ;
ASTOR, L ;
LEBECK, D ;
BRILLON, D ;
DIAMOND, B ;
VASILASDWOSKIN, A ;
LAURENZI, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (14) :977-986